A new genetic test from Invitrogen that can gauge a patient’s response to a new breast cancer drug was approved by The Food and Drug Aministration today, according to a story on CNNMoney.com.
Herceptin was the first of a new class of cancer drugs which destroy cancer cells without also killing normal cells. It works by targeting the HER-2 gene, which encourages tumor growth. However, only about 20 percent of breast cancer patients have cancer caused by the gene. . . .The Spotlight HER2 CISH test from Invitrogen identifies which patients are likely to respond to Herceptin based on the amount of HER-2 gene in their tumors.
Invitrogen stock was up 72 cents on the news.
[Link: CNNMoney.com]
RSS Feed-Posts
{ 0 comments… add one now }